

Melanoma: Assessment and Management - Committee Meeting 11

Date: 19th July 2021

Location: Zoom

Minutes: Final

Committee members present:		
Andrew Molyneux	Chair	Present for all
Guy Burkill	Radiologist	Present for Items 5-7
Dharmisha Chauhan	Co-opted Pharmacist	Present for all
Susan Cheetham	Lay member	Present for all
Fiona Collier	GP	Present for all
Sarah Hemington-Gorse	Plastic Surgeon	Present for all
Ian James	Lay member	Present for all
Lynne Jamieson	Histopathologist	Present for all
John Lear	Dermatologist	Present for all
Christine Parkinson	Medical Oncologist	Present for all
Saskia Reeken	Clinical nurse specialist	Present for all
Myles Smith	General Surgeon	Present for all
Delia Sworm	Oncology nurse specialist	Present for all
Steven Watkins	Oncologist	Present for all

In attendance:		
Steph Armstrong	NICE Technical Analyst, Health Economics	Present for all
Victoria Axe	NICE Guideline Commissioning Manager	Present for all
Rosanne Beijers (<i>Observing</i>)	NICE/ERS Fellow in Guideline Methodology	Present for all
Becky Chadwick	NICE Project Manager	Present for all
Lindsay Claxton	Technical Adviser, Health Economics	Present for all
Jeremy Dietz	NICE Technical Analyst, Health Economics	Present for Items
Brett Doble	NICE Technical Analyst, Health Economics	Present for all
Hannah Lomax (HL)	NICE Technical Analyst, Health Economics	Present for all
Tom Jarrett (TJ)	NICE Technical Analyst	Present for all
Judith McBride	NICE Senior Medical Editor	Present for all
Caroline Mulvihill	NICE Technical Analyst	Present for all
Joanna Perkin	Pathways Editor	Present for Items 1-2
Yang Song (<i>Observing</i>)	PhD Candidate	Present for all

Apologies:	
William Bolland	GP
Jenny Craven	NICE Information Services
Jacquelin Durkin	NICE Administrator
Gillian Godsell	Clinical nurse specialist
Stephen Keohane	Dermatologist
Howard Peach	Plastic Surgeon
Sue Spiers	NICE Associate Director
Sophie Wilne	Co-opted Paediatric Oncologist

Item 1

- Welcome
- DOIs
- Minutes from previous meeting

Andrew Molyneux (the Chair) welcomed the committee members and attendees to the eleventh committee meeting for the 'Melanoma: Assessment and Management' guideline. Apologies were noted as listed above.

Committee members were asked to declare any new interests that had occurred since the last meeting. No new interests were declared.

The minutes from committee meeting 10 (days 1 and 2) were approved as an accurate record of proceedings.

Item 2

- Pathways editor presentation

The Chair introduced NICE Pathways Editor Joanna Perkin (JP), who gave the Committee an overview of the purpose of NICE Pathways, and asked for volunteers to give input on the draft Pathway for this guideline.

The Chair thanked JP for her presentation and the Committee for their input.

Item 3

- RQ 5.1: Presentation of economic evidence

The Chair introduced NICE Technical Analyst, Health Economics, Hannah Lomax (HL), who presented on the economic evidence for RQ 5.1: *What is the most effective systemic and localised anticancer treatment for people with stage 4 (and unresectable stage 3) melanoma?*

The Chair thanked HL for her presentation and the Committee for their feedback.

Item 4

- RQ 4.2: Presentation of evidence

The Chair introduced NICE Technical Analyst Thomas Jarrett (TJ), who presented on the evidence for RQ 4.2: *What is the utility of sentinel lymph node biopsy for people with stage 3 melanoma and micro-satellite lesions?*. TJ then invited comments and questions from the Committee.

The Chair thanked TJ for his presentation and the Committee for their feedback.

Item 5

- RQ 2.1 & 6.1 revisited

NICE Technical Analyst Thomas Jarrett (TJ) revisited the evidence for RQ 2.1 and 6.1, and led a discussion of staging and the use of ultrasound during follow-up treatments.

The Chair thanked TJ for his presentation and the Committee for their feedback.

Item 6

- Potential algorithm for RQ 5.1

The NICE technical team led a brief discussion of a potential algorithm for RQ 5.1: *What is the most effective systemic and localised anticancer treatment for people with stage 4 (and unresectable stage 3) melanoma?*

The Chair thanked all for their input.

Item 7

- AOB, summary and next steps

The Chair thanked the committee for their contribution, summarised the main actions from the day and asked if there was any other business.

As there was no further business, the Chair highlighted the date of the next committee meeting and brought the meeting to a close.

Date of next meeting: Wednesday, 15th September 2021

Location of next meeting: Zoom